Aromatization of androgens into estrogens may explain some of the skeletal action of androgens. We examined the effect of the aromatase inhibitor Vorozole (VOR) on skeletal growth and mineral accumulation in growing 6-week-old male Wistar rats.
M
ANY ARGUMENTS favor the hypothesis that androgen action on bone could depend on aromatization of androgens into estrogens. In vitro, both androgen and estrogen receptors were shown to be present in male-derived human osteoblasts (1) . Although androgens may have direct effects on cultured osteoblasts (2) , osteoblasts were also shown to be able to aromatase androgens into estrogens (3) . Both androgens (4) and estrogens (5) inhibit osteoclastogenesis by decreasing interleukin-6 production in bone marrow stromal cells. In vivo, androgen and estrogen deficiency have similar skeletal effects in aged rats (6) . Estrogens inhibit bone resorption not only in male rats (6) but also in transsexual men (7) . Recently, both a man with an estrogen receptor deficiency (8) and another man with aromatase deficiency (9) were reported to have delayed skeletal growth and osteopenia. Also, both female and male estrogen receptor knock out mice may have a decreased bone density (10) . Finally, our group reported bone loss in aged male rats treated with the aromatase inhibitor VOR (11) . However, hypogonadism may also affect the growing skeleton. Indeed, it has been shown that androgen replacement in hypogonadal men is less effective when started after epiphyseal closure (12) . It is presently unclear to what extent the conversion of androgens into estrogens is important for the growing male skeleton. In growing gonadectomized male rats, both aromatizable and nonaromatizable androgens stimulate periosteal bone formation and increase bone size, but the effects of aromatase inhibition were not yet investigated (13) .
The aim of this study is therefore to compare the skeletal effects of VOR with effects of castration in growing male rats.
Material and Methods Animals
with VOR (20 mg/100 g) as to supply approximately 17 mg VOR/kg BW daily. The animals were fed ad libitum and had free access to tap water. Half of the animals received the control diet without VOR and half of the animals received the food mixed with VOR. Thus, four groups were created: Sham, Sham ϩ VOR, Orch, and Orch ϩ VOR. These groups were killed 18 weeks after surgery. Animals were weighted regularly during the experiment.
Animals were put in metabolic cages at regular intervals (see legend of Fig 2) for collection of 24 h urine for measurement of the collagen cross-links. Regularly, serum was obtained by tail bleeding for measurement of osteocalcin and IGF-I (see legend of Figs. 1 and 2).
For dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computerized tomography (pQCT), the femora were first defatted in trichloroethylene (Merck, Darmstadt, Germany) and dried. The lumbar vertebrae were cleaned from surrounding flesh and stored at Ϫ20 C until measurement by DXA. Serum was stored at Ϫ20 C.
All procedures were approved by the ethical committee of our university.
Assays
Serum osteocalcin (14) , IGF-I (15) and testosterone (16) were measured by an in-house RIA. Intraassay and interassay variation were respectively 5.9 and 5.2% for osteocalcin, 10.8 and 7.6% for IGF-1, and 3.5 and 5.1% for testosterone. Estradiol and its tetradeuterated internal standard were extracted from serum at neutral pH using diethyl ether. After an additional column purification, the residue was acylated using trifluoroacetic acid anhydride (TFA) and analyzed by gas chromatography coupled with high resolution mass spectrometry. The mass spec-
FIG. 1. Body weight and serum IGF-I in Sham and
Orch male rats treated with or without VOR. Dotted line represents average weight gain in normal female rats. A significant gain in body weight was observed in all groups (difference in time P Ͻ 0.001 according to Tukey's test), whereas serum IGF-I was not different at the end of the experiment compared with Base. A relative decrease of body weight gain compared with Sham (P Ͻ 0.0001) was similar in Orch, Orch ϩ VOR, and Sham ϩ VOR, whereas serum IGF-I was only lower in Sham ϩ VOR (P Ͻ 0.005).
FIG. 2.
Biochemical bone turnover parameters: serum osteocalcin, urinary pyridinoline, and deoxypyridinoline in Sham and Orch male rats treated with or without VOR. A significant decrease for all three biochemical parameters during the experimental period was observed (P Ͻ 0.001). A relative increase of all three parameters was observed in both Orch groups compared with both Sham groups, which was more pronounced in Orch than in Orch ϩ VOR (P Ͻ 0.001).
trometer was set to monitor the accurate molecular mass of estradiol-TFA and 2H 4 -estradiol-TFA. Urinary excretion of collagen cross-links [deoxypyridinoline (DPD) and pyridinoline (PYD)] was measured by HPLC as described (17) . Intra-and interassay coëfficients of variation were respectively 8.6% and 10.2% for PYD, 12 and 12.3% for DPD.
Dual energy x-ray absorptiometry (DXA)
The right femur was scanned with the Hologic QDR-100 as described (18) . Total area and bone mineral content (BMC) were measured; total bone mineral density (BMD) was calculated as bone mineral content/ area. Bone mineral density was also calculated for an area containing only cortical bone at the middle femur area and an area containing both cortical and cancellous bone at the distal femur. The first four lumbar vertebrae were selected on the screen and their area, mass, and density were calculated. The results are given as total area, BMC and BMD for the combined four lumbar vertebrae.
pQCT
The defatted specimens were placed in a specially constructed vial and mounted in the Stratec XCT 960A densitometer (Dutoit Medical, Wommelgem, Belgium) with a special support. Two CT-slices of each 1 mm thickness were obtained using a voxel size of 0.022 mm 3 . The slice taken at 6 mm proximal from the distal end of the femur gave data of trabecular bone density using a 0.53 cm Ϫ1 attenuation setting, whereas the second slice at 15 mm represented cortical bone where the attenuation threshold was 0.93 cm Ϫ1 . Both slices were calculated with special software with the following settings: contour mode 1, peel mode 20 and cortical mode 1. Femoral outer diameter, inner diameter and cortical thickness were measured at the diaphyseal part of the femur using the pQCT software and assuming a circular shape for the midfemur. Cortical thickness is calculated from the difference in total bone area and trabecular area assuming a circular ring model as described by Louis et al., 1995 (19) . The reproductivity (CV) of measurements for trabecular BMD and for cortical thickness are 2-3% and for cortical BMD 0.5%. Moreover, we found in a different experiment a correlation between TBMD and histomorphometrically determined BV/TV of r ϭ 0.9.
In the diaphyseal region, the software also provided data of the second moment of inertia.
Statistical analysis
Statistical analysis was performed using a statistical package (NCSS, Kaysville, UT). All data are expressed as mean Ϯ sem. A Tukey's honest significant difference multiple comparison test was used to find out if a parameter changed with time and if this change with time was different between groups. This test was only used separately for those parameters that were regularly followed during the experiment, such as body weight, serum IGF-1, osteocalcin and urinary (deoxy)pyridinolines, as presented in the Figs. 1 and 2.
Two-way ANOVA was for all other parameters used to determine the effects of orchidectomy, VOR, and their possible interaction at the end of the experiment, as presented in the tables and Fig. 3 . To be conservative in the application of the two-way ANOVA, one-way ANOVA with Tukey's test was applied when the interaction had a P value Յ 0.15. 
Results

General data, biochemical parameters of bone turnover, and serum IGF-I
As expected, body weight gain was significant in all groups (P Ͻ 0.0001) compared with Base ( Fig. 1a and Table  1 ). Serum IGF-1 was not significantly different between groups, except for a significant decrease of serum IGF-1 in Sham ϩ Vor, compared with Sham, Orch, and Orch ϩ VOR during the experimental period ( Fig. 1b and Table 1 ). At the end of study, weight gain was significantly lower, both in the Orch (-19%, P Ͻ 0.0001) and in the VOR groups (-29%, P Ͻ 0.0001). As expected, serum testosterone was only significantly decreased in orchidectomized animals ( Table 1) . Castration did not significantly reduce estradiol levels, whereas VOR did reduce estradiol levels to the same extent in both intact and castrated rats.
Serum osteocalcin, urinary PYR, and DPD decreased significantly during the experimental period compared with Base in all groups (P Ͻ 0.0001) (Fig. 2, a-c, respectively) . However, a relative increase of both serum osteocalcin as well as urinary DPD and PYR was observed in both orchidectomized groups (Orch and Orch ϩ VOR) compared with both Sham and Sham ϩ VOR (P Ͻ 0.0001) (Fig. 2, a-c,  respectively) . At the end of the experiment, however, both DPD and PYR (but not serum osteocalcin) were also significantly increased in Sham ϩ VOR compared with Sham ( Table 1) .
DXA of the femur and four distal lumbar vertebrae
Total area, BMC, and areal density of the femur and distal lumbar vertebrae increased, compared with Baseline (Table  2) . Total area, BMC and areal density of the femur and four distal lumbar vertebrae were significantly reduced both by orchidectomy and treatment with VOR, compared with Sham. Similar reductions were observed in a region of the femur that contains only cortical bone (middle femur) as well as in a region that contains both cortical and cancellous bone (distal femur) (significance was only reached in the Orch group for regional density). 
pQCT of the femur
Volumetric cortical density of the femur increased in all groups compared with Base. Volumetric cortical density, however, was similar in Sham, Sham ϩ VOR, Orch, and Orch ϩ VOR. Volumetric trabecular density of the distal femur increased in Sham compared with Base. As expected, a significant 60% decrease of volumetric cancellous density compared with Sham was observed in the orchidectomized group. VOR treatment, however, also decreased trabecular bone density, although less than in Orch groups. Cortical and trabecular bone areas (and moments of inertia) increased in all groups compared with Base.
Cortical areas were smaller compared with Sham as a result of decreased radial growth in both Orch groups and in Sham ϩ VOR (Table 3) . Therefore, lower moments of inertia were calculated in these groups compared with Sham.
Compared with Baseline, femoral length increased in all groups (Fig. 3) , but the relative increase was lower after orchidectomy. Compared with baseline, radial growth as measured by femoral outer diameter also increased, but this increase was significantly lower in both Orch groups and in the Sham ϩ VOR compared with Sham. Femoral inner diameter did not increase compared with Base in the Shamoperated control group. The inner femoral diameter decreased however in both Orch groups and in the ShamϩVOR group, compared with Sham and Base.
Femoral cortical thickness was, however, only decreased after orchidectomy.
Discussion
As expected, orchidectomy of growing male rats reduced bone size as a result of decreased skeletal modeling. This finding is consistent with earlier findings, not only in orchidectomized (13) but also in androgen resistant male rats (20). Moreover, both nonaromatizable and aromatizable androgens stimulate periosteal bone formation in gonadectomized male rats presumably via direct stimulation of the androgen receptor (13) . All these observations give strength to the hypothesis that androgens are anabolic agents for bone (21) and that sexual dimorphism of the skeleton ultimately depends on the presence of androgens.
Surprisingly, as a result of VOR treatment, skeletal size and modeling were reduced to a similar extent as by orchidectomy. These findings were unexpected. Indeed, these data suggest that androgens need aromatization into estrogens and therefore that skeletal modeling in male rats would be estrogen dependent. This would be completely opposite to the well-established inhibitory effects of estrogens on skeletal modeling in the female rat (13) . Earlier observations of reduced skeletal modeling in androgen resistant male rats with increased estrogen concentrations also do not fit with a direct stimulatory effect of estrogens on skeletal modeling in the male (20). Moreover, nonaromatizable androgens without estrogenic activity were shown to have stimulatory effects on skeletal modeling in male orchidectomized rats (13) .
An alternative explanation for the unexpected decrease in skeletal modeling observed in VOR-treated rats could be the decrease of mechanical load of the skeleton as the result of the lower body weight gain. Clearly, the inhibition of conversion of androgens into estrogens leads to a decrease in body weight gain to a similar extent as obtained by orchidectomy. Such a decrease of mechanical load may also switch off skeletal modeling drifts, at the periosteal and endosteal envelopes (22). Both VOR in this and earlier experiments (11) and estrogens (6) were shown to suppress growth in male rats. This may seem contradictory. However, also androgens were shown to be stimulatory for growth at lower concentrations and inhibitory at higher concentrations in male rats (23). Moreover, the inhibitory effects of androgens on growth were attributed to stimulation of the estrogen receptor (23). Therefore, the effects of both androgens and estrogens on growth may be concentration dependent with lower concentrations being stimulatory and higher concentrations inhibitory.
The finding that VOR (and not orchidectomy) decreases serum IGF-1, as described earlier (11), may be an important observation in this respect. It has indeed been shown that administration of IGF-1 to growing rats increases bone size (24). Moreover, preliminary unpublished findings in our laboratory suggest that VOR treatment also significantly decreases lean body mass. Therefore, its effect on skeletal modeling may be indirect through its effect on lean body mass with or without its interaction with serum IGF-1 concentrations.
Not only skeletal size but also bone mass and density were equally affected by orchidectomy and aromatase inhibition in concordance with earlier observations in aged male rats (11) . The decrease of bone mass observed in both castrated and VOR-treated growing male rats was explained by a decrease of (cortical) bone size that was the result of a de- creased periosteal bone formation. Cortical bone density was not affected by either condition, whereas trabecular bone density was lower in both conditions. Whereas the effects of castration and aromatase inhibition on skeletal size, mass and density were similar, their respective effects on biochemical parameters of bone turnover were different. As expected, orchidectomy increased bone turnover as assessed by both biochemical parameters of bone formation such as serum osteocalcin, and biochemical parameters of bone resorption such as urinary (deoxy)pyridinoline (17) . It was also shown earlier that the increase of biochemical parameters of bone turnover in androgendeficient male rats correlates well, not only with histomorphometric measurements of bone turnover but also with important loss of cancellous bone (6) . The increase of bone turnover (certainly of serum osteocalcin) was clearly significantly lower in VOR-treated animals than in orchidectomized animals.
Therefore, it is surprising that in VOR-treated rats cancellous bone loss occurred without major changes in bone turnover. However, as measured by pQCT [which is more accurate than DXA for the measurement of cancellous bone (24)], relative cancellous bone loss was significantly lower in VOR-treated Sham operated rats, compared with the Orch groups. Moreover, VOR treatment did not significantly decrease cortical thickness in contrast with orchidectomy. These observations suggest that both androgens and estrogens may have synergistic effects on the skeleton. Recently, such a synergistic action of estrogens and androgens in the prevention of ovariectomy-induced bone loss has been observed in female rats (25). Low dose replacement therapy with 17␤-estradiol during VOR treatment could conclusively confirm our present hypothesis that estrogens may also have physiological skeletal effects in male rats, and such work is in progress. In the aged male rat model (age 12 months), however, 17␤-estradiol replacement by SILASTIC brand (Dow Corning, Midland, MI) implant (3 g/per day for 15 weeks) could largely correct the bone loss induced by VOR treatment (unpublished personal results). Overall, the treatment with VOR combined with castration had, as expected, similar effects as castration alone, suggesting that VOR has no direct toxic effects on bone.
Finally, these data may also be relevant in humans. Similar decreases of bone size and density were reported in hypogonadal males (12) . Because both bone size and bone density are believed to be important determinants of bone strength (26), hypogonadal men may be predisposed to osteoporosis later in life (27). Also, skeletal mineral gain during growth is crucial for final bone mass. Delayed puberty is associated with decreased bone density (28) and androgen treatment in hypogonadal men started after puberty does not restore bone mass and is far less effective in this respect than androgen therapy started before puberty (12) . In humans, androgen action during growth may also depend on the conversion into estrogens. Both a man with estrogen receptor deficiency (9) and another man with aromatase deficiency (10) were reported to have osteopenia and delayed epiphyseal closure. As in the male rat, estrogen deficiency probably switches off modeling drifts at periosteal and endosteal sites. The bone turnover parameters were more increased in these estrogen deficient humans than in our VOR-treated animals (9, 10). However, contrary to humans, rats lack Haversian remodeling and epiphyseal closure. Cortical osteopenia and delayed epiphyseal closure will therefore complete the picture of estrogen deficiency syndrome in humans.
We conclude that treatment of growing rats with an aromatase inhibitor such as VOR impairs skeletal modeling and decreases bone size and mass to a similar extent as orchidectomy. However, the increase in bone turnover and the decrease in bone density were more pronounced after orchidectomy than after treatment with VOR. 
Erratum
In our paper entitled "Structure, Characterization, and Expression of the Gene Encoding the Mouse Mel 1a Melatonin Receptor" (Roca et al., Endocrinology 137:3469 -3477, 1996), we reported that 1.1 kb of the 5Ј-flanking region of the mouse Mel 1a receptor gene drives luciferase expression 114-fold over basal levels in a murine retinal cell line (RT2-2). Since publication, we have discovered that the 1.1-kb 5Ј-flanking region was inadvertently subcloned into pGL3-Basic luciferase reporter vector rather than the intended pGL2-Basic luciferase reporter vector. Expression of the pGL3 vector in RT2-2 cells results in high basal levels of luciferase activity. The low basal luciferase activity reported for the pGL2 vector without insert is correct. Low basal levels of luciferase (determined with the pGL2 vector) were thus being compared with activity of the pGL3 vector containing the promoter, incorrectly labeled as pGL2ϩ Promoter in Fig. 5 . We have performed the originally intended experiment (n ϭ 3) and determined that the 1.1-kb 5Ј-flanking region subcloned in pGL2 actually drives luciferase activity 4.3-fold over basal levels (pGL2 without insert). Thus, the 1.1-kb 5Ј-flanking region has only modest promoter activity in RT2-2 cells. The basic conclusions and interpretations in our paper remain as originally stated.
